Aimed Bio

At a glance

Aimed Bio filed 64 disclosures in the last 12 months, including 10 insider, 8 5% holder and 1 earnings. The most recent key filing was on Sep 18.

Revenue for 2025 was ₩47.3B, up 302% on 2024. Operating margin was 43.9% against -3.5% a year earlier. Debt was 3% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩28.7B and operating profit of ₩4.6B.

The 2025 annual report lists 52 employees with an average tenure of 2.6 years and average pay of ₩69M, #624 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩141.3M each on average. It paid no cash dividend for 2025. 남도현 and related parties held 34.55% at year end.

From the 2025 annual report

Staff: 52 (23 men, 29 women), of whom 5 on fixed-term contracts. Total pay for the year: ₩3.3B. Directors and auditors: 5, paid ₩706.5M in total.

No cash dividend was paid for 2025.

Largest shareholder

남도현 holds 34.55%; with 0 related parties the group holds 34.55% of common shares at year end (from 46.25% at the start of the year).

Auditor: 대주회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary